Tag - AGLE

Markets

Stifel starts Aeglea Bio at buy; PT 90 cents

Stifel initiated coverage of Aeglea BioTherapeutics (NASDAQ:AGLE) with a “buy” rating and price target of 90 cents. The stock closed at 59 cents on July 24. Aeglea is a biotechnology company that is now focused on the...

July 25, 2023

Developments

Aeglea BioTherapeutics gets FDA rare pediatric disease designation for homocystinuria

Aeglea BioTherapeutics’ (NASDAQ:AGLE) ACN00177 received FDA rare pediatric disease designation for the treatment homocystinuria. Homocystinuria is a serious metabolic disorder characterized by elevated plasma...

December 1, 2020

Developments

Aeglea BioTherapeutics gets FDA breakthrough designation for pegzilarginase

Aeglea BioTherapeutics’ (NASDAQ:AGLE) pegzilarginase received FDA breakthrough therapy designation for the treatment of arginase 1 deficiency (ARG1-D). ARG1-D is a rare genetic childhood disease that causes severe...

July 25, 2019

Tag - AGLE

Stifel starts Aeglea Bio at buy; PT 90 cents

Aeglea BioTherapeutics gets FDA rare pediatric disease designation for homocystinuria

Aeglea BioTherapeutics gets FDA breakthrough designation for pegzilarginase

General

More